Vogelstein B, Lane D and Levine AJ (2000) Surfing the p53 network. Nature 408: 307–310.
Prives C and Hall PA (1999) The p53 pathway. J. Pathol. 187: 112–126.
Jeffrey PD, Gorina S and Pavletich NP (1995) Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267: 1498–1502.
Brooks CL and Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15: 164–171.
Appella E and Anderson CW (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268: 2764–2772.
Erster S and Moll UM (2005) Stress-induced p53 runs a transcription-independent death program. Biochem. Biophys. Res. Commun. 331: 843–850.
Ko LJ and Prives C (1996) p53: puzzle and paradigm. Genes Dev. 10: 1054–1072.
Hoh J, Jin S, Parrado T, Edington J, Levine AJ and Ott J (2002) The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl. Acad. Sci. USA 99: 8467–8472.
Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH and Levine AJ (2000) Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev. 14: 981–993.
Inga A, Storici F, Darden TA and Resnick MA (2002) Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol. Cell. Biol. 22: 8612–8625.
Tomso DJ, Inga A, Menendez D, Pittman GS, Campbell MR, Storici F, Bell DA and Resnick MA (2005) Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc. Natl. Acad. Sci. USA 102: 6431–6436.
Resnick MA, Tomso D, Inga A, Menendez D and Bell D (2005) Functional diversity in the gene network controlled by the master regulator p53 in humans. Cell Cycle 4: 1026–1029.
Zheng X and Chen X (2001) Aquaporin 3, a glycerol and water transporter, is regulated by p73 of the p53 family. FEBS Lett. 489: 4–7.
Johnson RA, Ince TA and Scotto KW (2001) Transcriptional repression by p53 through direct binding to a novel DNA element. J. Biol. Chem. 276: 27716–27720.
Contente A, Dittmer A, Koch MC, Roth J and Dobbelstein M (2002) A polymorphic microsatellite that mediates induction of PIG3 by p53. Nature Genet. 30: 315–320.
Walter K, Warnecke G, Bowater R, Deppert W and Kim EL (2005) tumor suppressor p53 binds with high affinity to CTG. CAG trinucleotide repeats and induces topological alterations in mismatched duplexes. J. Biol. Chem. 280: 42497–42507.
Resnick MA and Inga A (2003) Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc. Natl. Acad. Sci. USA 100: 9934–9939.
Jayaraman L and Prives C (1999) Covalent and noncovalent modifiers of the p53 protein. Cell Mol. Life Sci. 55: 76–87.
Kim E and Deppert W (2006) The versatile interactions of p53 with DNA: when flexibility serves specificity. Cell Death Differ. 13: 885–889.
Liu Y and Kulesz-Martin MF (2006) Sliding into home: facilitated p53 search for targets by the basic DNA binding domain. Cell Death Differ. 13: 881–884.
Cho Y, Gorina S, Jeffrey PD and Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346–355.
Klein C, Planker E, Diercks T, Kessler H, Kunkele KP, Lang K, Hansen S and Schwaiger M (2001) NMR spectroscopy reveals the solution dimerization interface of p53 core domains bound to their consensus DNA. J. Biol. Chem. 276: 49020–49027.
Rippin TM, Freund SM, Veprintsev DB and Fersht AR (2002) Recognition of DNA by p53 core domain and location of intermolecular contacts of cooperative binding. J. Mol. Biol. 319: 351–358.
McLure KG and Lee PW (1998) How p53 binds DNA as a tetramer. EMBO J. 17: 3342–3350.
Data available at International Agency for Research on Cancer TP53, database R8, available at www.iarc.fr/p53.
Bullock AN, Henckel J, DeDecker BS, Johnson CM, Nikolova PV, Proctor MR, Lane DP and Fersht AR (1997) Thermodynamic stability of wild-type and mutant p53 core domain. Proc. Natl. Acad. Sci. USA 94: 14338–14342.
Wong KB, DeDecker BS, Freund SM, Proctor MR, Bycroft M and Fersht AR (1999) Hot-spot mutants of p53 core domain evince characteristic local structural changes. Proc. Natl. Acad. Sci. USA 96: 8438–8442.
Bullock AN, Henckel J and Fersht AR (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19: 1245–1256.
Butler JS and Loh SN (2003) Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain. Biochemistry 42: 2396–2403.
Foster BA, Coffey HA, Morin MJ and Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507–2510.
Hansen S, Hupp TR and Lane DP (1996) Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC Cell Transformation Group. J. Biol. Chem. 271: 3917–3924.
Friedlander P, Legros Y, Soussi T and Prives C (1996) Regulation of mutant p53 temperature-sensitive DNA binding. J. Biol. Chem 271: 25468–25478.
Butler JS and Loh SN (2005) Kinetic partitioning during folding of the p53 DNA binding domain. J. Mol. Biol. 350: 906–918.
Di Como CJ, Gaiddon C and Prives C (1999) p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 9: 1438–1449.
Gaiddon C, Lokshin M, Ahn J, Zhang T and Prives C (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21: 1874–1887.
Bensaad K, Le Bras M, Unsal K, Strano S, Blandino G, Tominaga O, Rouillard D and Soussi T (2003) Change of conformation of the DNA-binding domain of p53 is the only key element for binding of and interference with p73. J. Biol. Chem. 278: 10546–10555.
Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T and Kaelin Jr WG (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25: 47–54.
Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK and Lozano G (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li–Fraumeni syndrome. Cell 119: 861–872.
Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D and Jacks T (2004) Mutant p53 gain of function in two mouse models of Li–Fraumeni syndrome. Cell 119: 847–860.
Chan WM, Siu WY, Lau A and Poon RY (2004) How many mutant p53 molecules are needed to inactivate a tetramer? Mol. Cell. Biol. 24: 3536–3551.
Ljungman M, O'Hagan HM and Paulsen MT (2001) Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation. Oncogene 20: 5964–5971.
Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E and Yao TP (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20: 1331–1340.
Rodriguez MS, Desterro JM, Lain S, Lane DP and Hay RT (2000) Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol. 20: 8458–8467.
Xirodimas DP, Saville MK, Bourdon JC, Hay RT and Lane DP (2004) Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118: 83–97.
Li M, Luo J, Brooks CL and Gu W (2002) Acetylation of p53 inhibits its ubiquitination by Mdm2. J. Biol. Chem. 277: 50607–50611.
Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gamblin SJ, Barlev NA and Reinberg D (2004) Regulation of p53 activity through lysine methylation. Nature 432: 353–360.
Muller S, Ledl A and Schmidt D (2004) SUMO: a regulator of gene expression and genome integrity. Oncogene 23: 1998–2008.
Ahn J and Prives C (2001) The C-terminus of p53: the more you learn the less you know. Nat. Struct. Biol. 8: 730–732.
Gu W and Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595–606.
Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW and Appella E (1998) DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12: 2831–2841.
Luo J, Li M, Tang Y, Laszkowska M, Roeder RG and Gu W (2004) Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. USA 101: 2259–2264.
Anderson ME, Woelker B, Reed M, Wang P and Tegtmeyer P (1997) Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: implications for regulation. Mol. Cell. Biol. 17: 6255–6264.
Ayed A, Mulder FA, Yi GS, Lu Y, Kay LE and Arrowsmith CH (2001) Latent and active p53 are identical in conformation. Nat. Struct. Biol. 8: 756–760.
Friedler A, Veprintsev DB, Freund SM, von Glos KI and Fersht AR (2005) Modulation of binding of DNA to the C-terminal domain of p53 by acetylation. Structure (Cambridge) 13: 629–636.
Espinosa JM and Emerson BM (2001) Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8: 57–69.
Kaeser MD and Iggo RD (2002) Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. USA 99: 95–100.
Krummel KA, Lee CJ, Toledo F and Wahl GM (2005) The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. USA 102: 10188–10193.
Feng L, Lin T, Uranishi H, Gu W and Xu Y (2005) Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell Biol. 25: 5389–5395.
McKinney K and Prives C (2002) Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol. Cell. Biol. 22: 6797–6808.
Fojta M, Pivonkova H, Brazdova M, Nemcova K, Palecek J and Vojtesek B (2004) Investigations of the supercoil-selective DNA binding of wild type p53 suggest a novel mechanism for controlling p53 function. Eur. J. Biochem. 271: 3865–3876.
Palecek E, Brazda V, Jagelska E, Pecinka P, Karlovska L and Brazdova M (2004) Enhancement of p53 sequence-specific binding by DNA supercoiling. Oncogene 23: 2119–2127.
McKinney K, Mattia M, Gottifredi V and Prives C (2004) p53 linear diffusion along DNA requires its C terminus. Mol. Cell 16: 413–424.
Liu Y, Lagowski JP, Vanderbeek GE and Kulesz-Martin MF (2004) Facilitated search for specific genomic targets by p53 C-terminal basic DNA binding domain. Cancer Biol. Ther. 3: 1102–1108.
Harms KL and Chen X (2005) The C terminus of p53 family proteins is a cell fate determinant. Mol. Cell. Biol. 25: 2014–2030.
Palecek E, Brazdova M, Cernocka H, Vlk D, Brazda V and Vojtesek B (1999) Effect of transition metals on binding of p53 protein to supercoiled DNA and to consensus sequence in DNA fragments. Oncogene 18: 3617–3625.
Okorokov AL and Milner J (1999) An ATP/ADP-dependent molecular switch regulates the stability of p53-DNA complexes. Mol. Cell. Biol. 19: 7501–7510.
McLure KG, Takagi M and Kastan MB (2004) NAD+ modulates p53 DNA binding specificity and function. Mol. Cell. Biol. 24: 9958–9967.
Nagaich AK, Appella E and Harrington RE (1997) DNA bending is essential for the site-specific recognition of DNA response elements by the DNA binding domain of the tumor suppressor protein p53. J. Biol. Chem. 272: 14842–14849.
Bell S, Klein C, Muller L, Hansen S and Buchner J (2002) p53 contains large unstructured regions in its native state. J. Mol. Biol. 322: 917–927.
Dawson R, Muller L, Dehner A, Klein C, Kessler H and Buchner J (2003) The N-terminal domain of p53 is natively unfolded. J. Mol. Biol. 332: 1131–1141.
Lee H, Mok KH, Muhandiram R, Park KH, Suk JE, Kim DH, Chang J, Sung YC, Choi KY and Han KH (2000) Local structural elements in the mostly unstructured transcriptional activation domain of human p53. J. Biol. Chem. 275: 29426–29432.
Lin JY, Chen JD, Elenbaas B and Levine AJ (1994) Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Gene Dev. 8: 1235–1246.
Candau R, Scolnick DM, Darpino P, Ying CY, Halazonetis TD and Berger SL (1997) Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity. Oncogene 15: 807–816.
Chang J, Kim DH, Lee SW, Choi KY and Sung YC (1995) Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein. J. Biol. Chem. 270: 25014–25019.
Zilfou JT, Hoffman WH, Sank M, George DL and Murphy M (2001) The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol. Cell. Biol. 21: 3974–3985.
Zheng H, You H, Zhou XZ, Murray SA, Uchida T, Wulf G, Gu L, Tang X, Lu KP and Xiao ZX (2002) The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419: 849–853.
Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C and Del Sal G (2002) The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature 419: 853–857.
Dornan D, Shimizu H, Burch L, Smith AJ and Hupp TR (2003) The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol. Cell. Biol. 23: 8846–8861.
Curtin JC and Spinella MJ (2005) p53 in human embryonal carcinoma: identification of a transferable, transcriptional repression domain in the N-terminal region of p53. Oncogene 24: 1481–1490.
Bond GL, Hu W and Levine AJ (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets 5: 3–8.
Zhang Y and Xiong Y (2001) A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Science 292: 1910–1915.
Shieh S-Y, Ikeda M, Taya Y and Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325–334.
Chehab NH, Malikzay A, Stavridi ES and Halazonetis TD (1999) Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc. Natl. Acad. Sci. USA 96: 13777–13782.
Dumaz N and Meek DW (1999) Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 18: 7002–7010.
Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R and Brady JN (1998) Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem. 273: 33048–33053.
Saito S, Goodarzi AA, Higashimoto Y, Noda Y, Lees-Miller SP, Appella E and Anderson CW (2002) ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J. Biol. Chem. 277: 12491–12494.
Mayo LD, Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar CK and Donner DB (2005) Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J. Biol. Chem. 280: 25953–25959.
Saito S, Yamaguchi H, Higashimoto Y, Chao C, Xu Y, Fornace Jr AJ, Appella E and Anderson CW (2003) Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J. Biol. Chem. 278: 37536–37544.
Ashcroft M, Kubbutat MH and Vousden KH (1999) Regulation of p53 function and stability by phosphorylation. Mol. Cell Biol. 19: 1751–1758.
Thompson T, Tovar C, Yang H, Carvajal D, Vu BT, Xu Q, Wahl GM, Heimbrook DC and Vassilev LT (2004) Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J. Biol. Chem. 279: 53015–53022.
Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS, Wang W, Kashanchi F and Shiekhattar R (2000) BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 102: 257–265.
Lee D, Kim JW, Seo T, Hwang SG, Choi EJ and Choe J (2002) SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J. Biol. Chem. 277: 22330–22337.
Hill DA, de la Serna IL, Veal TM and Imbalzano AN (2004) BRCA1 interacts with dominant negative SWI/SNF enzymes without affecting hom*ologous recombination or radiation-induced gene activation of p21 or Mdm2. J. Cell Biochem. 91: 987–998.
Hsu CH, Chang MD, Tai KY, Yang YT, Wang PS, Chen CJ, Wang YH, Lee SC, Wu CW and Juan LJ (2004) HCMV IE2-mediated inhibition of HAT activity downregulates p53 function. EMBO J. 23: 2269–2280.
Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD and Berger SL (2001) Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8: 1243–1254.
Lill NL, Grossman SR, Ginsberg D, DeCaprio J and Livingston DM (1997) Binding and modulation of p53 by p300/CBP coactivators. Nature 387: 823–827.
Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS and Kelly K (1997) Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89: 1175–1184.
An W, Kim J and Roeder RG (2004) Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117: 735–748.
Gu W, Malik S, Ito M, Yuan CX, Fondell JD, Zhang X, Martinez E, Qin J and Roeder RG (1999) A novel human SRB/MED-containing cofactor complex, SMCC, involved in transcription regulation. Mol. Cell 3: 97–108.
Zhang X, Krutchinsky A, f*ckuda A, Chen W, Yamamura S, Chait BT and Roeder RG (2005) MED1/TRAP220 exists predominantly in a TRAP/Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. Mol. Cell 19: 89–100.
Xing J, Sheppard HM, Corneillie SI and Liu X (2001) p53 Stimulates TFIID-TFIIA-promoter complex assembly, and p53-T antigen complex inhibits TATA binding protein-TATA interaction. Mol. Cell Biol. 21: 3652–3661.
Graunke DM, Fornace Jr AJ and Pieper RO (1999) Presetting of chromatin structure and transcription factor binding poise the human GADD45 gene for rapid transcriptional up-regulation. Nucleic Acids Res. 27: 3881–3890.
Xiao G, White D and Bargonetti J (1998) p53 binds to a constitutively nucleosome free region of the mdm2 gene. Oncogene 16: 1171–1181.
Braastad CD, Han Z and Hendrickson EA (2003) Constitutive DNase I hypersensitivity of p53-regulated promoters. J. Biol. Chem. 278: 8261–8268.
Harms K, Nozell S and Chen X (2004) The common and distinct target genes of the p53 family transcription factors. Cell. Mol. Life Sci. 61: 822–842.
Yu J and Zhang L (2005) The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun. 331: 851–858.
Mirza A, Wu Q, Wang L, McClanahan T, Bishop WR, Gheyas F, Ding W, Hutchins B, Hockenberry T, Kirschmeier P, Greene JR and Liu S (2003) Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene 22: 3645–3654.
Burns TF and El-Deiry WS (2003) Microarray analysis of p53 target gene expression patterns in the spleen and thymus in response to ionizing radiation. Cancer Biol. Ther. 2: 431–443.
Sax JK, Stoddard A, Murphy ME, Chodosh L and El-Deiry WS (2003) Microarray expression profiling of p53-dependent transcriptional changes in an immortalized mouse embryo fibroblast cell line. Cancer Biol. Ther. 2: 416–430.
Robinson M, Jiang P, Cui J, Li J, Wang Y, Swaroop M, Madore S, Lawrence TS and Sun Y (2003) Global genechip profiling to identify genes responsive to p53-induced growth arrest and apoptosis in human lung carcinoma cells. Cancer Biol. Ther. 2: 406–415.
Zhu N, Gu L, Findley HW and Zhou M (2005) Transcriptional repression of the eukaryotic initiation factor 4E gene by wild type p53. Biochem. Biophys. Res. Commun. 335: 1272–1279.
Kim E, Gunther W, Yoshizato K, Meissner H, Zapf S, Nusing RM, Yamamoto H, Van Meir EG, Deppert W and Giese A (2003) Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. Oncogene 22: 7716–7727.
Maiyar AC, Phu PT, Huang AJ and Firestone GL (1997) Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein. Mol. Endocrinol. 11: 312–329.
Liu G, Schwartz JA and Brooks SC (1999) p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. Biochem. Biophys. Res. Commun. 264: 359–364.
Maeda Y, Seidel SD, Wei G, Liu X and Sladek FM (2002) Repression of hepatocyte nuclear factor 4alpha tumor suppressor p53: involvement of the ligand-binding domain and histone deacetylase activity. Mol. Endocrinol. 16: 402–410.
Gu L, Zhu N, Findley HW, Woods WG and Zhou M (2004) Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively. J. Biol. Chem. 279: 52141–52149.
St Clair S, Giono L, Varmeh-Ziaie S, Resnick-Silverman L, Liu WJ, Padi A, Dastidar J, DaCosta A, Mattia M and Manfredi JJ (2004) DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol. Cell 16: 725–736.
Ori A, Zauberman A, Doitsh G, Paran N, Oren M and Shaul Y (1998) p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. EMBO J. 17: 544–553.
Lee KC, Crowe AJ and Barton MC (1999) p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol. Cell Biol. 19: 1279–1288.
Li B and Lee MY (2001) Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1. J. Biol. Chem. 276: 29729–29739.
Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A and Dannenberg AJ (1999) Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 274: 10911–10915.
Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ and George DL (1999) Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13: 2490–2501.
Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW, Kastan M and Giaccia A (2001) Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol. Cell Biol. 21: 1297–1310.
Ho JS, Ma W, Mao DY and Benchimol S (2005) p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol. Cell Biol. 25: 7423–7431.
Johnson RA, Shepard EM and Scotto KW (2005) Differential regulation of MDR1 transcription by the p53 family members. Role of the DNA binding domain. J. Biol. Chem. 280: 13213–13219.
Sengupta S, Shimamoto A, Koshiji M, Pedeux R, Rusin M, Spillare EA, Shen JC, Huang LE, Lindor NM, Furuichi Y and Harris CC (2005) Tumor suppressor p53 represses transcription of RECQ4 helicase. Oncogene 24: 1738–1748.
Chun AC and Jin DY (2003) Transcriptional regulation of mitotic checkpoint gene MAD1 by p53. J. Biol. Chem. 278: 37439–37450.
Wilkinson DS, Ogden SK, Stratton SA, Piechan JL, Nguyen TT, Smulian GA and Barton MC (2005) A direct intersection between p53 and transforming growth factor beta pathways targets chromatin modification and transcription repression of the alpha-fetoprotein gene. Mol. Cell Biol. 25: 1200–1212.
Rocha S, Martin AM, Meek DW and Perkins ND (2003) p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol. Cell Biol. 23: 4713–4727.
Gottifredi V, Karni-Schmidt O, Shieh SS and Prives C (2001) p53 down-regulates CHK1 through p21 and the retinoblastoma protein. Mol. Cell Biol. 21: 1066–1076.
Lohr K, Moritz C, Contente A and Dobbelstein M (2003) p21/CDKN1A mediates negative regulation of transcription by p53. J. Biol. Chem. 278: 32507–32516.
Murphy M, Hinman A and Levine AJ (1996) Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev. 10: 2971–2980.
Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L and Debussche L (1998) The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17: 4668–4679.
Li J, Tan M, Li L, Pamarthy D, Lawrence TS and Sun Y (2005) SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing. Neoplasia 7: 312–323.
Gridasova AA and Henry RW (2005) The p53 tumor suppressor protein represses human snRNA gene transcription by RNA polymerases II and III independently of sequence-specific DNA binding. Mol. Cell Biol. 25: 3247–3260.
Zhai W and Comai L (2000) Repression of RNA polymerase I transcription by the tumor suppressor p53. Mol. Cell Biol. 20: 5930–5938.
Budde A and Grummt I (1999) p53 represses ribosomal gene transcription. Oncogene 18: 1119–1124.
Stein T, Crighton D, Warnock LJ, Milner J and White RJ (2002) Several regions of p53 are involved in repression of RNA polymerase III transcription. Oncogene 21: 5540–5547.
Crighton D, Woiwode A, Zhang C, Mandavia N, Morton JP, Warnock LJ, Milner J, White RJ and Johnson DL (2003) p53 represses RNA polymerase III transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB. EMBO J. 22: 2810–2820.
Eichhorn K and Jackson SP (2001) A role for TAF3B2 in the repression of human RNA polymerase III transcription in nonproliferating cells. J. Biol. Chem. 276: 21158–21165.
Cairns CA and White RJ (1998) p53 is a general repressor of RNA polymerase III transcription. EMBO J. 17: 3112–3123.
Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK and Lane DP (2005) p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19: 2122–2137.
Rohaly G, Chemnitz J, Dehde S, Nunez AM, Heukeshoven J, Deppert W and Dornreiter I (2005) A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 122: 21–32.
Harms KL and Chen X (2006) The functional domains in p53 family proteins exhibit both common and distinct properties. Cell Death Differ. 13: 890–897.
